The German drugmaker reported a 9.7% jump in overall sales over the first half of 2023, largely thanks to growth in Eli Lilly-partnered SGLT2 inhibitor Jardiance. Human pharmaceutical products made up 9.6 billion euros ($10.5 billion) of the total sales haul, good for 11.3% growth, with animal health products contributing the rest of Boehringer’s 12.2 billion euros ($13.2 billion) in total revenue.
The Jardiance franchise generated 3.5 billion euros ($3.83 billion) for Boehringer over this year’s first half. Looking forward, the company expects further growth as Jardiance progresses in chronic kidney disease (CKD), with a U.S. decision expected to come later this year following a recent European Commission go-ahead. In a late-stage trial, the drug was the first SGLT2 inhibitor to post a reduction in all-cause hospitalizations for CKD patients while reducing disease progression or death by 28% compared with placebo.
An FDA nod would add to Jardiance’s wide reach, which already includes Type 2 diabetes and heart failure. Later this year, the company will report data from the drug's phase 3 trial in myocardial infarction.
“Persistent and above-average investments in our pipeline during the last years have resulted in many new treatment options for patients in the years to come, thus transforming lives for generations,” Boehringer's chairman of the board, Hubertus von Baumbach, noted in the company's release.
Elsewhere, Boehringer’s Humira biosimilar recently launched as the first interchangeable option in the U.S. The company is currently pricing the med 5% to 7% below Humira’s list price but will turn to a two-price strategy in 2024.
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.